No Data
WuXi AppTec Reports Q1 Results
WuXi AppTec Co., (WUXIF) Ltd. Q1 2025 Earnings Call Transcript Summary
BEIGENE's revenue growth in 2024, narrowing losses, and core products gaining global traction.
① The company achieved a revenue of 27.214 billion yuan for the year, with a year-on-year increase of 56.19%; the net income attributable to shareholders was -4.978 billion yuan, a decrease of 17.38% from the previous year; the net income excluding non-recurring items was -5.379 billion yuan, a year-on-year decrease of 17.38%; ② The revenue share of Baiyueze and Baizean continues to expand, driving the company's revenue growth.
WUXI APPTEC: Q1 net profit significantly increased, maintaining double-digit growth guidance for the year | Interpretations
① WUXI APPTEC's Q1 net income attributable to the parent company grew 89.1% year-on-year, mainly due to revenue growth, improved overall profitability, and the sale of WUXI XDC stocks; ② WUXI APPTEC still believes it can achieve its annual double-digit growth target.
WUXI APPTEC: Q1 revenue of 9.655 billion yuan, a year-on-year growth of 21%, with strong performance in the Business driving significant growth.
WUXI APPTEC's first quarter of 2025: strong performance growth driven by the chemical Business, TIDES Business revenue surged by 187%. Key financial highlights...
Summit Therapeutics Shares Are Trading Lower. The Company's Partner Akeso Received FDA Approval for Its PD-1 Monoclonal Antibody, Penpulimab-kcqx, in Combination With Cisplatin or Carboplatin and Gemcitabine. The FDA Also Approved Penpulimab-kcqx as a...
